Infectious Disease (BK22995) Stock Forum and Discussion - Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Investment ThemesDetailed Quotes

Infectious Disease Watchlist

923.992
-2.356-0.25%

Close Mar 26 16:00 ET

929.598High920.815Low

Constituent Stocks: 18Top Rising: GILD+1.28%

Sign in to post a comment

$Pfizer (PFE.US)$
ok i am in

1

Look at all these Fake News media pumping FUD.

I guess whoever is behind this didn't get the results they wanted. PFE only drops by about 29 cents.
Shorting over 100M, you better have something more than this. You are going to get the mother of all squeeze (MOAS)!
$Pfizer (PFE.US)$ $SPDR S&P 500 ETF (SPY.US)$

Look at all these Fake News media pumping FUD.

Look at all these Fake News media pumping FUD.

US Prosecutors Investigate Tip on Pfizer Vaccine, Wall Street Journal Reports

1

1

$Pfizer (PFE.US)$
Added some shares at 25.39 to DCA.

1

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung canc

$Johnson & Johnson (JNJ.US)$
Game-Changing Clinical Data: New Cancer Drug Combo Extends Survival by 12+ Months

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung canc

$Pfizer (PFE.US)$
Pharma businesses are resilient to economic recession.

3

Oh boy… there’s some money behind this… but usually, big money avoids dividend stocks. This isn’t normal…

4

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

$Johnson & Johnson (JNJ.US)$
Breakthrough Phase 3 Results: New Drug Shows Promise for Myasthenia Gravis, Including Pregnant Patients

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older

$GlaxoSmithKline (GSK.US)$
Breakthrough: New UTI Antibiotic Blujepa Shows Superior Results in Clinical Trials

Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

$AstraZeneca (AZN.US)$
Major Breakthrough: AstraZeneca's TAGRISSO Extends Lung Cancer Survival to Nearly 5 Years

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

ひな☆彡 SOXL ♡

Yesterday 04:34

$Johnson & Johnson (JNJ.US)$
with yesterday’s breakout, it tocuhed the day bolinger. I expect more drop. hopefully in next several trading days.

J&J Update

RIPPER: ABOUT TIME……We have a breakout from neckline. Plenty of time to still enter this one. First target is 159, second target is 152.

1

2

No comment yet